| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2123396 | European Journal of Cancer | 2010 | 9 Pages |
Abstract
Patient-reported QOL deteriorated significantly among survival-favourable ERCC1-neg patients possibly due to increased toxicity especially in patients with adenocarcinomas. Our novel findings emphasise strict demands for careful patient selection, proper methodology and prospective validation of ERCC1 to prove a true survival benefit before clinical implementation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Adam Vilmar, Eric Santoni-Rugiu, Jens Benn Sørensen,